Literature DB >> 11106681

Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism.

B J Maurer1, L Melton, C Billups, M C Cabot, C P Reynolds.   

Abstract

BACKGROUND: We previously reported that N-(4-hydroxyphenyl)retinamide (4-HPR, fenretinide) treatment caused large increases of ceramide levels in neuroblastoma cell lines and induced cell death by a combination of apoptosis and necrosis through p53 (also known as TP53)-independent and caspase-independent pathways. Our goal was to determine if several molecules that inhibit enzymes involved in ceramide metabolism-L-threo-dihydrosphingosine (safingol), d, l-threo-1-phenyl-2-hexadecanoylamino-3-morpholino-1-propanol (PPMP), and tamoxifen-enhanced 4-HPR-mediated cytotoxicity and/or affected ceramide levels.
METHODS: Cellular lipids were quantified by radiolabeling and thin-layer chromatography. Cytotoxicity and cytotoxic synergy (expressed as combination index, where combination index <1 indicates synergy and >1 indicates antagonism) were measured in cultured cancer cell lines with the use of a fluorescence-based assay of cell viability employing digital imaging microscopy. Statistical tests were two-sided.
RESULTS: 4-HPR increased ceramide levels by de novo synthesis. Safingol (1-4 microM) was incorporated into a stereochemical variant of ceramide and synergized with a 3:1 molar ratio of 4-HPR (3-12 microM), to produce a 100-fold to 10 000-fold (2 to 4 logs) increase in cytotoxicity relative to 4-HPR alone in neuroblastoma (combination index <0.1), lung (combination index <0.1-0.2), melanoma (combination index <0.1-0.2), prostate (combination index <0.1-1.0), colon (combination index 0.1-0.3), breast (combination index = 0.1-0.5), and pancreas (combination index = 0.2) cell lines, including p53 mutant and alkylator-resistant cell lines. The 4-HPR and safingol combination was cytotoxic in low-oxygen conditions and was minimally toxic to normal fibroblasts and bone marrow myeloid progenitor cells. Addition of agents that retard ceramide glucosylation and/or acylation, such as PPMP or tamoxifen, to 4-HPR or to the combination of 4-HPR and safingol further increased cytotoxicity to tumor cells.
CONCLUSIONS: Combinations of 4-HPR and modulators of ceramide metabolism may form the basis for a novel chemotherapy that is functional under hypoxic conditions (e.g., such as those within tumors) and is p53 independent and caspase independent.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11106681     DOI: 10.1093/jnci/92.23.1897

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  56 in total

Review 1.  The therapeutic potential of modulating the ceramide/sphingomyelin pathway.

Authors:  Richard Kolesnick
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

2.  Fenretinide targets chronic myeloid leukemia stem/progenitor cells by regulation of redox signaling.

Authors:  Yanzhi Du; Yuan Xia; Xiaoling Pan; Zi Chen; Aihua Wang; Kankan Wang; Junmin Li; Ji Zhang
Journal:  Antioxid Redox Signal       Date:  2013-10-24       Impact factor: 8.401

Review 3.  p53 and regulation of bioactive sphingolipids.

Authors:  Linda A Heffernan-Stroud; Lina M Obeid
Journal:  Adv Enzyme Regul       Date:  2010-10-28

Review 4.  Targeting sphingolipid metabolism in head and neck cancer: rational therapeutic potentials.

Authors:  Thomas H Beckham; Saeed Elojeimy; Joseph C Cheng; Lorianne S Turner; Stanley R Hoffman; James S Norris; Xiang Liu
Journal:  Expert Opin Ther Targets       Date:  2010-05       Impact factor: 6.902

5.  Phase I trial of fenretinide lym-x-sorb oral powder in adults with solid tumors and lymphomas.

Authors:  Shivaani Kummar; Martin E Gutierrez; Barry J Maurer; C Patrick Reynolds; Min Kang; Hardeep Singh; Sonja Crandon; Anthony J Murgo; James H Doroshow
Journal:  Anticancer Res       Date:  2011-03       Impact factor: 2.480

Review 6.  Tamoxifen regulation of sphingolipid metabolism--Therapeutic implications.

Authors:  Samy A F Morad; Myles C Cabot
Journal:  Biochim Biophys Acta       Date:  2015-05-09

7.  Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial.

Authors:  Ann M Mohrbacher; Allen S Yang; Susan Groshen; Shivaani Kummar; Martin E Gutierrez; Min H Kang; Denice Tsao-Wei; C Patrick Reynolds; Edward M Newman; Barry J Maurer
Journal:  Clin Cancer Res       Date:  2017-04-18       Impact factor: 12.531

8.  Modification of sphingolipid metabolism by tamoxifen and N-desmethyltamoxifen in acute myelogenous leukemia--Impact on enzyme activity and response to cytotoxics.

Authors:  Samy A F Morad; Su-Fern Tan; David J Feith; Mark Kester; David F Claxton; Thomas P Loughran; Brian M Barth; Todd E Fox; Myles C Cabot
Journal:  Biochim Biophys Acta       Date:  2015-03-10

9.  Potentiation of cannabinoid-induced cytotoxicity in mantle cell lymphoma through modulation of ceramide metabolism.

Authors:  Kristin Gustafsson; Birgitta Sander; Jacek Bielawski; Yusuf A Hannun; Jenny Flygare
Journal:  Mol Cancer Res       Date:  2009-07       Impact factor: 5.852

10.  Role for PKC δ in Fenretinide-Mediated Apoptosis in Lymphoid Leukemia Cells.

Authors:  Vivian R Ruvolo; Kul B Karanjeet; Todd F Schuster; Rhoderick Brown; Yibin Deng; Edward Hinchcliffe; Peter P Ruvolo
Journal:  J Signal Transduct       Date:  2010-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.